Combined Administration of Intravenous and Topical Tranexamic Acid in Total Knee Arthroplasty
- Registration Number
- NCT02286973
- Lead Sponsor
- Seoul National University Hospital
- Brief Summary
This prospective randomized controlled trial was conducted To compare the efficacy of TNA in terms of total blood loss and the allogenic transfusion rate among the three study groups; intravenous alone, combined intravenous and low dose topical TNA and combined intravenous and high dose topical TNA.
To evaluate the safety of each regimen in view of deep vein thrombosis and venous thromboembolism.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 264
Inclusion Criteria
- patients with diagnosis of primary osteoarthritis
Exclusion Criteria
- patients with diagnoses other than primary OA
- patients on anticoagulation therapy
- patient with chronic renal failure
- patient with CVA Hx
- Patient with seizure Hx
- Patient with severe CHF
- Patient with acquired or congenital coagulopathy
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Only Intravenous Group Tranexamic Acid Only Intravenous Injection During Operation, 10mg/kr Intravenous + Topical 1g Group Tranexamic Acid Intravenous Injection During Operation, 10mg/kr After Capsule Closure, Tranexamic acid Topical Injection 1g Intravenous + Topical 2g Group Tranexamic Acid Intravenous Injection During Operation, 10mg/kr After Capsule Closure, Tranexamic acid Topical Injection 2g No Intravenous, Only Topical 2g Group Tranexamic Acid Only Topical Injection 2g
- Primary Outcome Measures
Name Time Method Change in Hemoglobin baseline and 5 days Blood loss reduce
- Secondary Outcome Measures
Name Time Method